ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL
A comprehensive analysis of Venetoclax-Obinutuzumab (Ven-Obi) in treating chronic lymphocytic leukemia (CLL) reveals its effectiveness and tolerability across different patient profiles.